Harbour gets ex-China rights to Kelun's anti-PD-L1 mAb

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. granted Harbour BioMed (Shanghai, China) exclusive rights to anti-PD-L1 antibody A167 outside of the Greater

Read the full 206 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE